A review of validation strategies for computational drug repositioning

Briefings in Bioinformatics

Volumn 19, Issue 1, 2018, Pages 174-177

  Brown, Adam S ^a   Patel, Chirag J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Analytic validation; Drug repositioning; Research reproducibility

Indexed keywords

BIOLOGY; COMPUTER SIMULATION; DRUG REPOSITIONING; FACTUAL DATABASE; HUMAN; PROCEDURES; VALIDATION STUDY;

COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DATABASES, FACTUAL; DRUG REPOSITIONING; HUMANS; VALIDATION STUDIES AS TOPIC;

EID: 85041192028     PISSN: 14675463     EISSN: 14774054     Source Type: Journal    
DOI: 10.1093/bib/bbw110     Document Type: Article

References (22)

1. Rodriguez-Esteban R. A drug-centric view of drug development: how drugs spread from disease to disease. PLoS Comput Biol 2016;12:e1004852.
2. Li J, Zheng S, Chen B, et al. A survey of current trends in computational drug repositioning. Brief Bioinform 2016;17:2-12.
3. Lamb J, Crawford ED, Peck D, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-35.
4. Gottlieb A, Stein GY, Ruppin E, et al. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol 2011;7:496.
5. Huang H, Nguyen T, Ibrahim S, et al. DMAP: a connectivity map database to enable identification of novel drug repositioning candidates. BMC Bioinformatics 2015;16(Suppl 13):S4.
6. Brown AS, Kong SW, Kohane IS, et al. ksRepo: a generalized platform for computational drug repositioning. BMC Bioinformatics 2016;17:78.
7. Qu XA, Gudivada RC, Jegga AG, et al. Inferring novel disease indications for known drugs by semantically linking drug action and disease mechanism relationships. BMC Bioinformatics 2009;10(Suppl 5):S4.
8. Cheung WA, Ouellette BFF, Wasserman WW. Quantitative biomedical annotation using medical subject heading overrepresentation profiles (MeSHOPs). BMC Bioinformatics 2012;13:249.
9. Kissa M, Tsatsaronis G, Schroeder M. Prediction of drug gene associations via ontological profile similarity with application to drug repositioning. Methods 2015;74:71-82.
10. Patchala J, Jegga AG. Conceptmodeling-based drug repositioning. AMIA Jt Summits Transl Sci Proc 2015;2015:222-6.
11. Ryan PB, Madigan D, Stang PE, et al. Medication-wide association studies. CPT Pharmacometrics Syst Pharmacol 2013;2:e76.
12. Xu H, Aldrich MC, Chen Q, et al. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc 2015;22:179-91.
13. Pahikkala T, Airola A, Pietila S, et al. Toward more realistic drug-target interaction predictions. Brief Bioinform 2015;16: 325-37.
14. Wishart DS, Knox C, Guo AC, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006;34:D668-72.
15. Davis AP, Grondin CJ, Lennon-Hopkins K, et al. The comparative toxicogenomics database's 10th year anniversary: update Nucleic Acids Res 2015;43:D914-20.
16. Sirota M, Dudley JT, Kim J, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 2011;3:96ra77.
17. Jung J, Lee D. Inferring disease association using clinical factors in a combinatorial manner and their use in drug repositioning. Bioinformatics 2013;29:2017-23.
18. Thorn CF, Klein TE, Altman RB. PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. Methods Mol Biol 2005;311:179-91.
19. Zhu F, Shi Z, Qin C, et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res 2012;40:D1128-36.
20. Lever J, Krzywinski M, Altman N. Points of significance: model selection and overfitting. Nat Methods 2016;13: 703-4.
21. Fawcett T. An introduction to ROC analysis. Pattern Recognit Lett 2006;27:861-74.
22. Hanczar B, Hua J, Sima C, et al. Small-sample precision of ROC-related estimates. Bioinformatics 2010;26:822-30.